Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Developmental Disorder Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NOTCH2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NOTCH2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View NOTCH2 Products |
| Gene Delivery | NOTCH2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View NOTCH2 Products |
| Benchmark Ab | Anti-NOTCH2 (Sequence of Tarextumab) Recombinant positive control. |
View NOTCH2 Products |
| Validator | NOTCH2 siRNA Set For knockdown verification. |
View NOTCH2 Products |
| Related Target A | NOTCH1 Critical for off-target selectivity screening to avoid severe gastrointestinal toxicity. |
View NOTCH1 Products |
| Related Target B | DLL4 Key Notch ligand involved in tumor angiogenesis and synergistic pathway signaling. |
View DLL4 Products |
| Related Target C | JAG1 Ligand implicated in Alagille syndrome and Notch2-mediated oncogenesis. |
View JAG1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High homology among NOTCH family receptors | Human/Mouse/Cyno ortholog proteins available with >95% purity for precise cross-reactivity profiling. |
| Disulfide-rich, complex EGF-like repeat folding | HEK293 mammalian expression system ensures native post-translational O-glycosylation and correct folding. |
| Lack of reliable positive control references | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| Off-target assay interference | Sequence-verified, endotoxin-controlled recombinant proteins prevent non-specific cellular responses. |
Live NOTCH2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NOTCH2 therapeutics is intensifying, with major players shifting focus from traditional pan-Notch gamma-secretase inhibitors (GSIs) to highly selective monoclonal antibodies and bispecific agents. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective epitope blockades to decouple therapeutic efficacy from systemic intestinal toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | OncoMed Pharmaceuticals, GSK | Solid Tumors, Pancreatic Cancer | Ligand-blocking assays (Need high-purity ECD-Fc and biotinylated ligands) |
| Bispecific Antibody (bsAb) | AbbVie, Celgene | Ovarian Cancer, Breast Cancer | Dual-targeting validation (Need cross-reactive ortholog proteins) |
| Small Molecule Inhibitors | SpringWorks Therapeutics, Ay ancestral | Desmoid Tumors, Adenoid Cystic Carcinoma | Selectivity assays against NOTCH1/3/4 (Need complete recombinant protein panel) |